Sugi Predict

Sugi Predict / Compounds / SCHEMBL24876

SCHEMBL24876

SCHEMBL24876

CCOC(=O)/C=C/c1cccc(F)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ MAPT P10636 3/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ TP53 P04637 1/20 0.65
▸ GAA P10253 1/20 0.65
▸ TTR P02766 1/20 0.60
▸ DPP4 P27487 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ CA12 O43570 1/20 0.56
▸ CA1 P00915 1/20 0.56
▸ CA2 P00918 1/20 0.56
▸ CA7 P43166 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ CA14 Q9ULX7 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ MAOB P27338 2/20 0.55
▸ EGFR P00533 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24877 1.00 MEN1 (0.65) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL1207521 0.90 MEN1 (0.56) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL1207522 0.90 MEN1 (0.56) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL9167221 0.89 MEN1 (0.55) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL9167224 0.89 MEN1 (0.55) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL4427602 0.89 TTR (0.69) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL4427604 0.89 TTR (0.69) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL1269502 0.84 TTR (0.63) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL1269501 0.84 TTR (0.63) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL3752885 0.84 CA12 (0.69) TTRDPP4CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 — — WO disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 — — EP disclosed
US-20200165205-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 — — US disclosed
US-10590085-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-03-17 — — US disclosed
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-17 — — US disclosed
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-17 — — US disclosed
EP-1040111-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-10-04 — — EP disclosed
US-6090944-A Alkanoic acid derivatives as αv integrin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 — — US disclosed
US-6066648-A USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH MERCK & CO., INC. (US) 2000-05-23 — — US disclosed
US-6017926-A Integrin receptor antagonists MERCK & CO., INC. (US) 2000-01-25 — — US disclosed
US-5981546-A Integrin antagonists MERCK & CO., INC. (US) 1999-11-09 — — US disclosed
EP-0934305-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-08-11 — — EP disclosed
WO-1999030709-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 — — WO disclosed
WO-1999030713-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 — — WO disclosed
WO-1999031099-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 — — WO disclosed
WO-1998008840-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590085-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 MEN1 1603/4885KMT2A 487/4885MAPT 3677/4885
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors MAP3K19, MAP3K20, MAP3K1 MEN1 1767/4885KMT2A 475/4885MAPT 3638/4885
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 MEN1 1767/4885KMT2A 475/4885MAPT 3638/4885
US-11485710-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 MEN1 1767/4885KMT2A 475/4885MAPT 3638/4885
US-20200165205-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 MEN1 1767/4885KMT2A 475/4885MAPT 3638/4885
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 MEN1 1603/4885KMT2A 487/4885MAPT 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.